Humanised Igg1 Monoclonal Antibody Against Tfr1 Conjugated To Double Stranded Sirna Oligonucleotide Against Dmpk Via A Non-Cleavable Linker

2 trials 1 recruiting Orphan designation

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

1 Recruiting

1 Completed trials

1 Sponsors

7 Countries

Phase III

Phase III: 2

Sponsors using this IMP

Avidity Biosciences Inc. 2

All trials

2 total

A Global Phase 3 Open-Label Extension Study to Assess AOC 1001 in Patients with DM1 Recruiting

2025-520766-22-00 Phase III 6 countries Avidity Biosciences Inc.
A Phase 3 Global Study to Evaluate AOC 1001 for the Treatment of Myotonic Dystrophy Type 1 Ended

2024-511378-60-00 Phase III 7 countries Avidity Biosciences Inc.

Showing 1–2 of 2 trials

← All drugs A–Z